Latest Insider Transactions at Genocea Biosciences, Inc. (GNCA)
This section provides a real-time view of insider transactions for Genocea Biosciences, Inc. (GNCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENOCEA BIOSCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENOCEA BIOSCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2022
|
William D Clark President and CEO |
SELL
Open market or private sale
|
Direct |
4,023
-1.3%
|
$0
$0.06 P/Share
|
|
Jun 02
2022
|
Jessica Baker Flechtner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,578
-1.74%
|
$0
$0.06 P/Share
|
|
Jun 02
2022
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,355
-1.77%
|
$0
$0.06 P/Share
|
|
Jun 01
2022
|
Jacquelyn L Sumer CHIEF LEGAL & COMPLIANCE OFF |
SELL
Open market or private sale
|
Direct |
2,500
-5.49%
|
$0
$0.06 P/Share
|
|
May 31
2022
|
William D Clark President and CEO |
SELL
Open market or private sale
|
Direct |
117,244
-27.55%
|
$0
$0.06 P/Share
|
|
May 27
2022
|
George Siber Director |
SELL
Open market or private sale
|
Direct |
20,425
-98.78%
|
$0
$0.07 P/Share
|
|
May 26
2022
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
24,407
-24.13%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Jessica Baker Flechtner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,525
-15.43%
|
$0
$0.09 P/Share
|
|
May 25
2022
|
Raymond D Stapleton Jr CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-5.41%
|
$0
$0.09 P/Share
|
|
May 25
2022
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Ali Behbahani Director |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Carmen Chang > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Anthony A. Florence Jr. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Mohamad Makhzoumi > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
New Enterprise Associates 16, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Peter W. Sonsini > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Paul Edward Walker > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 24
2022
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Ali Behbahani Director |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Carmen Chang > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Anthony A. Florence Jr. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Mohamad Makhzoumi > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
New Enterprise Associates 16, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Peter W. Sonsini > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Paul Edward Walker > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
Apr 04
2022
|
Girish N Aakalu CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
963
-1.28%
|
$963
$1.25 P/Share
|
|
Apr 04
2022
|
William D Clark President and CEO |
SELL
Open market or private sale
|
Direct |
3,924
-1.05%
|
$3,924
$1.25 P/Share
|
|
Apr 04
2022
|
Thomas Andrew Davis CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,091
-1.57%
|
$1,091
$1.25 P/Share
|
|
Apr 04
2022
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
963
-1.04%
|
$963
$1.25 P/Share
|
|
Apr 04
2022
|
Jessica Baker Flechtner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,212
-1.24%
|
$1,212
$1.25 P/Share
|
|
Mar 16
2022
|
Girish N Aakalu CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
2,397
-3.08%
|
$2,397
$1.1 P/Share
|
|
Mar 16
2022
|
William D Clark President and CEO |
SELL
Open market or private sale
|
Direct |
11,435
-2.97%
|
$11,435
$1.1 P/Share
|
|
Mar 16
2022
|
Thomas Andrew Davis CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,717
-3.77%
|
$2,717
$1.1 P/Share
|
|
Mar 16
2022
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,873
-3.0%
|
$2,873
$1.1 P/Share
|
|
Mar 16
2022
|
Jessica Baker Flechtner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,349
-3.32%
|
$3,349
$1.1 P/Share
|
|
Mar 15
2022
|
Girish N Aakalu CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+28.65%
|
-
|
|
Mar 15
2022
|
William D Clark President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+28.05%
|
-
|
|
Mar 15
2022
|
Thomas Andrew Davis CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+30.23%
|
-
|
|
Mar 15
2022
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+28.17%
|
-
|
|
Mar 15
2022
|
Jessica Baker Flechtner Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+30.28%
|
-
|
|
Mar 15
2022
|
Raymond D Stapleton Jr CHIEF TECHNOLOGY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+48.61%
|
-
|
|
Mar 15
2022
|
Jacquelyn L Sumer CHIEF LEGAL & COMPLIANCE OFF |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+45.18%
|
-
|
|
Mar 15
2021
|
Thomas Andrew Davis CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+50.0%
|
-
|
|
Mar 15
2021
|
Girish N Aakalu CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+50.0%
|
-
|
|
Mar 15
2021
|
Jessica Baker Flechtner Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+50.0%
|
-
|
|
Mar 15
2021
|
William D Clark President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Mar 15
2021
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Feb 17
2021
|
William D Clark President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,498
+25.63%
|
$72,996
$2.19 P/Share
|